Blog

Numerous Scenarios –  One Software

Cakev2

The expression, “you can’t have your cake and eat it too,” is all too familiar to most, particularly in healthcare. When referencing a glucose management tool, rumor has it that a software should be used regularly, or, for treating “difficult” scenarios, but not always both. This thought process needs to be stopped.

A software such as EndoTool Glucose Management System is not only personalized for a stable patient, but also specializes in the most “difficult” scenarios.

When a stable patient is treated with EndoTool, the software recommends insulin based on unique response to insulin and patient parameters such as: blood glucose level, Diabetes Mellitus (DM) type, age, sex, weight, sCr, eGFR, steroids, and any estimated residual extracellular insulin (EREI). In addition to this, more than 60 combined algorithms ensure that dosing is individualized and responsive to ongoing changes in each patient’s unique physiological response.

What about a more complicated scenario such as Diabetic ketoacidosis (when the body cannot produce enough insulin and begins to burn fat for energy while producing a buildup of acids in the bloodstream)? Treatment takes place in the hospital and typically involves fluid replacement, electrolyte replacement, and insulin therapy. The software to treat DKA is the same software to dose a stable patient. The response to insulin therapy, unique parameters, and combined algorithms are still there, working hard to recommend your next dose.

In fact, even in the most difficult patient scenarios, such as DKA and HNS, EndoTool provides a safe and efficient solution for glucose management with 99.4% of all patients achieving control.

The next time someone says, “you can’t have your cake and eat it too,” introduce them to EndoTool, because you can. Every hospital can have the best of both worlds by using one glucose management tool for countless circumstances.

Does your CGM incorporate EREI?

EREI-v2

Even though the protocol for dosing insulin can be carefully calculated for the particular patient in need, what if that patient’s need for insulin changes quickly after the initial dose recommendation? This concept is not only unheard of, it is very common. Based on a wide range of factors, such as a patient’s activity level, meals consumed, and stress, a patient’s insulin may change. In this case, the dosing of insulin needs to reflect that change. read more…

Delight. Delight. Delight.

Businessman drawing Custome Satisfaction concept on blurred abstract background

Do you know what Amazon, Marriott, Apple, UPS, and FedEx have in common?

According to USA Today and MSN’s Customer Service Survey, these companies have been ranked among the top 25 large companies to achieve a reputation of exceptional customer service.

Customer service, or customer delight, is surprising a customer by exceeding their expectations and creating a positive emotional reaction which leads to a stronger relationship. Why is this idea so important? When people like you, they want to work with you, so it is critical to not only make a great first impression, but to maintain it. read more…

Glycemic Targets Pt. 1 – SMBG & CGM

Dartv2

One of the most critical responsibilities of patients with diabetes is patient self-monitoring of blood glucose (SMBG). In order to assess glycemic levels, SMBG is available to caregivers and patients to evaluate the safety of the suggested glycemic management plan. It is not only important to check blood glucose levels, but continuous glucose monitoring (CGM) is essential to create a treatment plan for type 1 and type 2 diabetes.

Per the Standards of Medical Care in Diabetes, recommendations are as follows: read more…

Insulin 101

Insulin_v2

Let’s get back to the basics. Per The American Diabetes Association, insulin is a naturally occurring hormone secreted by the pancreas. Many people with type 1 diabetes are prescribed insulin because their bodies do not produce insulin, and insulin can be necessary for people with type 2 diabetes because their bodies do not use insulin properly. read more…

Artificial Intelligence behind EndoTool – A tool, not a replacement

Nurse touch her tablet with copy space for text display.

Earlier this month, the blog titled ‘Innovative Thinking > Product Selling’ summarized the idea of selling a concept instead of selling a product. The article informed the reader that in order to sell an innovative technology, they have to not only change what executives think, but also how they think.

When it comes to recommending an insulin dose for hospitalized patients, EndoTool replaces dated and linear protocols with personalized patient treatment. The magic behind EndoTool’s innovation is to use sophisticated and predictive algorithms to optimize insulin dosing for even the most complex patients. In turn, institutions avoid costly hospital acquired infections and hospital acquired conditions as the result of poor glucose control. read more…

The Risk of Hypoglycemia in Type 2 Diabetes

Diabetes-Type-2_v2

Hypoglycemia is a condition characterized by abnormally low blood glucose (blood sugar) levels, usually less than 70 mg/dL. This condition is recognized to be one of the main restrictions in achieving normal control in type 1 diabetes. Historically, the risk of hypoglycemia has been considered lower in type 2 diabetes, however, with the increasing use of insulin to treat type 2 diabetes, the occurrence of hypoglycemia has the potential to intensify.

The focus on the relationship between hypoglycemia and type 1 diabetes is due to the frequency of hypoglycemia in these patients. Per the American Diabetes Association, on average, people with type 1 diabetes experience hypoglycemia around twice a week. This number equates to a prevalence of 30% – 40% a year. read more…

Monarch Medical Technologies Announces New Chief Executive Officer

Monarch Medical Technologies, the market-leading clinical decision support software committed to the safest insulin dosing, today announced that Linda Beneze has joined the company as its new chief executive officer. Formerly the Chief Executive Officer at Medical Technology Products, Beneze has extensive experience building and leading global high-performance teams with expertise in medical device, clinical trial software, bioinformatics, and data management.

“After an extensive selection process, we are delighted to have Linda Beneze lead the company in an evolving and expanding market of inpatient glycemic control. Linda brings a wealth of experience in improving outcomes and enhancing patient and provider safety, alongside her unique blend of leadership experience,” said Christophe Mallard, managing member of private investment firm Eigen Capital Holdings LLC which controls Monarch Medical Technologies. “Linda shares our commitment to patient safety, passion for improving hospital outcomes, and excitement for our future. We look forward to strong continued growth under her leadership.” read more…

Innovative Thinking > Product Selling

Innovative-03-01-17-v2

Recently, an article written by Prashant Dedhia was shared on LinkedIn titled, ‘Don’t sell a product, sell a whole new way of thinking’. The mantra of selling an idea instead of a product is a concept often overlooked in healthcare.

In order to sell innovative technology to executives, you have to not only change what those people think, but how they think. The author writes about companies that successfully market and sell innovation and are able to shift how people think not only about their product, but about themselves, the market, and the world. read more…

Page 1 of 912345...Last »